Stanford University |
Katja Weinacht |
Quest - Discovery Stage Research Projects |
Regenerative Thymic Tissues as Curative Cell Therapy for Patients with 22q11 Deletion Syndrome |
$1,251,720 |
University of California, San Diego |
Eric Adler |
Quest - Discovery Stage Research Projects |
Genetically Modified Hematopoietic Stem Cells for the Treatment of Danon Disease |
$1,393,200 |
University of California, Los Angeles |
Lili Yang |
Quest - Discovery Stage Research Projects |
Preclinical Development of An HSC-Engineered Off-The-Shelf iNKT Cell Therapy for Cancer |
$1,404,000 |
Gladstone Institutes, J. David |
Li Gan |
Quest - Discovery Stage Research Projects |
Develop iPSC-derived microglia to treat progranulin-deficient Frontotemporal Dementia |
$1,547,157 |
Salk Institute for Biological Studies |
Ronald Evans |
Quest - Discovery Stage Research Projects |
Therapeutic immune tolerant human islet-like organoids (HILOs) for Type 1 Diabetes |
$1,637,209 |
University of California, San Francisco |
Krystof Bankiewicz |
Late Stage Preclinical Projects |
MRI Guided Delivery of Neural Progenitor Cells Secreting GDNF for the Treatment of Parkinson's disease |
$5,811,340 |
City of Hope, Beckman Research Institute |
John Zaia |
Late Stage Preclinical Projects |
Ex Vivo Gene Engineering of Blood Stem Cells for Enhanced Chemotherapy Efficacy in Glioblastoma Patients |
$3,684,259 |
University of California, Los Angeles |
Steven Dubinett |
Clinical Trial Stage Projects |
A phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC |
$10,955,315 |
MAX BioPharma, Inc. |
Farhad Parhami |
Therapeutic Translational Research Projects |
Therapeutic development of Oxy200, an oxysterol with bone anabolic and anti-resorptive properties for intervention in osteoporosis |
$1,400,000 |
University of California, Irvine |
Magdalene Seiler |
Therapeutic Translational Research Projects |
Morphological and functional integration of stem cell derived retina organoid sheets into degenerating retina models |
$4,769,039 |
Stanford University |
Bertha Chen |
Therapeutic Translational Research Projects |
Autologous iPSC-derived smooth muscle cell therapy for treatment of urinary incontinence |
$5,977,155 |
UCSF Benioff Children’s Hospital Oakland |
Henry Erlich |
Diagnostic Translational Research Projects |
Development of a Noninvasive Prenatal Test for Beta-Hemoglobinopathies for Earlier Stem Cell Therapeutic Interventions |
$1,074,177 |
University of California, San Francisco |
Steven Mack |
Diagnostic Translational Research Projects |
Development of a Noninvasive Prenatal Test for Beta-Hemoglobinopathies for Earlier Stem Cell Therapeutic Interventions |
$633,014 |
Stanford University |
David Miklos |
Clinical Trial Stage Projects |
Phase 1 Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Malignancies |
$11,034,982 |
Sangamo BioSciences, Inc. |
Bettina Cockroft |
Clinical Trial Stage Projects |
A Phase 1/2 Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous HSPC Transplant in Transfusion-dependent β-Thalassemia |
$5,150,000 |
University of California, San Francisco |
Morton Cowan |
Clinical Trial Stage Projects |
Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency Using a Lentiviral Vector to Transduce Autologous CD34 Hematopoietic Stem Cells |
$12,000,000 |
Fate Therapeutics, Inc. |
Bob Valamehr |
Late Stage Preclinical Projects |
IND enabling development of FT516: A Natural Killer Cell Immunotherapy for Cancer Derived from a Human Inducible Pluripotent Stem Cell |
$4,000,000 |
City of Hope, Beckman Research Institute |
De-Fu Zeng |
Clinical Trial Stage Projects |
Treatment of sickle cell disease by induction of mixed chimerism and immune tolerance using CD4+ T-depleted haploidentical blood stem cell transplant |
$4,352,180 |
Medeor Therapeutics, Inc. |
Daniel Brennan |
Clinical Trial Stage Projects |
Cellular Immunotherapy for Induction of Immune Tolerance in HLA Matched Living Donor Kidney Transplant Recipients |
$11,217,155 |
Keystone Symposia on Molecular and Cellular Biology |
Thale Jarvis |
Conference II |
iPSCs: A Decade of Progress and Beyond |
$35,000 |
University of California, San Francisco |
David Rowitch |
Conference II |
“Myelin Through the Ages: Evolution, Development, Degeneration and Disease” - 2018 Gordon Research Conference (GRC) and Gordon Research Seminar (GRS) |
$10,000 |
International Society for Stem Cell Research |
Glori Rosenson |
Conference II |
ISSCR 2019 Nucleus Forum |
$24,000 |
International Society for Stem Cell Research |
Cathy Vijeh |
Conference II |
ISSCR 2019 |
$50,000 |
Stanford University |
Joseph Wu |
Conference II |
2018 Stanford Drug Discovery and Stem Cell Technology Conference |
$15,000 |
The Regents of the University of California on behalf of its Riverside Campus |
Xiaoping Hu |
Conference II |
19th Annual UC System-wide Bioengineering Symposium |
$14,536 |
University of California, Los Angeles |
John Adams |
Conference - The 2018 Alpha Stem Cell Clinic Annual Symposium |
Delivery of Stem Cell Therapeutics to Patients |
$60,000 |
University of California, Irvine |
Leslie Thompson |
Conference II |
Stem Cells for Huntington’s Disease (HD) International (SC4HDI) Conference |
$31,727 |
City of Hope, Beckman Research Institute |
Saswati Chatterjee |
Quest - Discovery Stage Research Projects |
Genome Editing of Sinusoidal Endothelial Stem Cells for Permanent Correction of Hemophilia A |
$2,182,193 |
Neurona Therapeutics |
Cory Nicholas |
Quest - Discovery Stage Research Projects |
Development of a Cellular Therapeutic for Treatment of Epilepsy |
$1,616,536 |
University of California, San Diego |
Yang Xu |
Quest - Discovery Stage Research Projects |
Development of immune invisible beta cells as a cell therapy for type 1 diabetes through genetic modification of hESCs |
$1,924,791 |
ViaCyte, Inc. |
Alan Agulnick |
Quest - Discovery Stage Research Projects |
Preclinical development of an immune evasive islet cell replacement therapy for type 1 diabetes |
$1,470,987 |
Stanford University |
Helen Blau |
Quest - Discovery Stage Research Projects |
Stimulating endogenous muscle stem cells to counter muscle atrophy |
$2,198,687 |
University of California, San Diego |
Mark Tuszynski |
Quest - Discovery Stage Research Projects |
Neural Stem Cell Relays for Severe Spinal Cord Injury |
$1,638,900 |
Stanford University |
Kyle Loh |
Quest - Discovery Stage Research Projects |
Towards hepatocyte cell replacement therapy: developing a renewable source of human hepatocytes from pluripotent stem cells |
$1,968,456 |
University of California, Los Angeles |
April Pyle |
Quest - Discovery Stage Research Projects |
Identification and Generation of Long Term Repopulating Human Muscle Stem Cells from Human Pluripotent Stem Cells |
$2,148,519 |
University of California, Los Angeles |
Stanley Carmichael |
Quest - Discovery Stage Research Projects |
iPS Glial Therapy for White Matter Stroke and Vascular Dementia |
$2,086,130 |
University of California, San Diego |
Tannishtha Reya |
Quest - Discovery Stage Research Projects |
Targeting Cancer Stem Cells in Hematologic Malignancies |
$1,960,560 |
University of California, Los Angeles |
Scott Kitchen |
Quest - Discovery Stage Research Projects |
Engineering Lifelong Cellular Immunity to HIV |
$1,701,178 |
University of California, San Francisco |
Shuvo Roy |
Quest - Discovery Stage Research Projects |
Silicon Nanopore Membrane encapsulated enriched-Beta Clusters for Type 1 Diabetes treatment |
$1,113,000 |
University of California, Irvine |
Aileen Anderson |
Quest - Discovery Stage Research Projects |
Generation and in vitro profiling of neural stem cell lines to predict in vivo efficacy for chronic cervical spinal cord injury. |
$1,575,613 |
University of California, Los Angeles |
Alireza Moshaverinia |
Inception - Discovery Stage Research Projects |
Gingival mesenchymal stem cells as a novel treatment modality for periodontal tissue regeneration |
$194,483 |
Stanford University |
Anthony Oro |
Therapeutic Translational Research Projects |
DEBCT: Genetically Corrected, Induced Pluripotent Cell-Derived Epithelial Sheets for Definitive Treatment of Dystrophic Epidermolysis Bullosa |
$5,107,353 |
University of California, San Diego |
Karl Wahlin |
Inception - Discovery Stage Research Projects |
An IPSC cell based model of macular degeneration for drug discovery. |
$232,200 |
University of California, San Diego |
Catriona Jamieson |
Therapeutic Translational Research Projects |
A Splicing Modulator Targeting Cancer Stem Cells in Acute Myeloid Leukemia |
$2,511,767 |
University of California, San Diego |
Dan Kaufman |
Therapeutic Translational Research Projects |
Human Embryonic Stem Cell-Derived Natural Killer Cells for Cancer Treatment |
$3,260,000 |
University of California, San Francisco |
Semil Choksi |
Inception - Discovery Stage Research Projects |
Generation of human airway stem cells by direct transcriptional reprogramming for disease modeling and regeneration |
$238,408 |
Stanford University |
Guillem Pratx |
Inception - Discovery Stage Research Projects |
Novel metabolic labeling method for tracking stem cells to irradiated salivary glands using PET |
$229,227 |
University of California, Davis |
Alyssa Panitch |
Inception - Discovery Stage Research Projects |
Development of treatments to improve healing of ischemic wounds |
$235,099 |
University of California, San Diego |
Gerald Morris |
Inception - Discovery Stage Research Projects |
Identification of antigenic neo-epitopes from in vitro reprogrammed human tissue precursors for regenerative therapy |
$193,500 |
Stanford University |
Hiromitsu Nakauchi |
Inception - Discovery Stage Research Projects |
Optimizing self-renewal signaling kinetics to stabilize ex vivo hematopoietic stem cell expansion |
$210,906 |
Human BioMolecular Research Institute |
John Cashman |
Inception - Discovery Stage Research Projects |
Human Pancreatic Cancer Stem Cells: Developing a Novel Drug for Cancer Eradication |
$303,785 |
Loma Linda University |
Julia Unternaehrer-Hamm |
Inception - Discovery Stage Research Projects |
Targeting cancer stem cells with nanoparticle RNAi delivery to prevent recurrence and metastasis of ovarian cancer |
$172,870 |
University of California, Davis |
Alice Tarantal |
Inception - Discovery Stage Research Projects |
Enhanced Branching Morphogenesis and Pluripotent Cell Lineage Differentiation for Pediatric Regenerative Therapies |
$235,800 |
Palo Alto Veterans Institute for Research |
Ngan Huang |
Inception - Discovery Stage Research Projects |
iPSC-Derived Smooth Muscle Progenitors for Treatment of Abdominal Aortic Aneurysm |
$172,621 |
Loma Linda University |
David Baylink |
Inception - Discovery Stage Research Projects |
Bone Marrow Targeting of Hematopoietic Stem Cells Engineered to Overexpress 25-OH-VD3 1-α-hydroxylase for Acute Myeloid Leukemia Therapy |
$178,967 |
Cedars-Sinai Medical Center |
Dmitriy Sheyn |
Inception - Discovery Stage Research Projects |
IVD rejuvenation using iPSC-derived notochordal cells |
$241,992 |
Zenobia Therapeutics |
Vicki Nienaber |
Inception - Discovery Stage Research Projects |
A new phenotypic screening platform that identifies biologically-relevant targets and lead compounds for the treatment of Parkinson’s disease |
$112,500 |
California State University San Marcos Corporation |
Bianca Mothe |
Conference - Manage The Bridges Annual Meeting |
2018 and 2019 Bridges Annual Meeting |
$291,622 |
Calibr |
Kristen Johnson |
Clinical Trial Stage Projects |
Evaluation of the Safety and Tolerability of KA34 in a Phase 1, Double-Blind, Dose Escalation Trial in Patients with Knee Osteoarthritis |
$8,447,523 |
Children's Hospital of Los Angeles |
Michael Pulsipher |
Clinical Trial Stage Projects |
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) |
$4,825,587 |
Poseida Therapeutics, Inc. |
Rajesh Belani |
Clinical Trial Stage Projects |
Clinical Study of T stem cell memory (Tscm)-based CAR-T cells in Patients with Multiple Myeloma |
$19,813,407 |
University of California, Davis |
Gerhard Bauer |
Conference - Manage The SPARK Annual Meeting |
The 2018 SPARK Annual Meeting |
$39,391 |
RUNX1 Research Program |
Timothy Babich |
Conference II |
Living with and Curing RUNX1 FPD/AML Forum |
$9,500 |
Alliance Forum Foundation |
George Hara |
Conference II |
2017 World Alliance Forum in San Francisco (WAFSF) "Healthcare Game Changers" |
$5,000 |
Stanford University |
Matthew Porteus |
Late Stage Preclinical Projects |
Genome Editing of Autologous Hematopoietic Stem Cells to Treat Sickle Cell Disease |
$4,849,363 |
Nohla Therapeutics Inc |
Colleen Delaney |
Clinical Trial Stage Projects |
A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Optimal Dose-Finding Study of DCC-UCB in Adults Receiving High Dose Chemotherapy for AML |
$4,310,000 |
ViaCyte, Inc. |
Manasi Jaiman |
Clinical Trial Stage Projects |
Clinical trial of directly vascularized islet cell replacement therapy for high-risk type 1 diabetes |
$13,607,002 |
Humacyte, Inc. |
Jeffrey Lawson |
Clinical Trial Stage Projects |
A Phase 3 Study Comparing the Utility of Human Acellular Vessels to Arteriovenous Fistula in Subjects with End-Stage Renal Disease (California Sites) |
$3,525,000 |
City of Hope, Beckman Research Institute |
Christine Brown |
Clinical Trial Stage Projects |
Phase I Study of Chimeric Antigen Receptor Engineered Central Memory T cells for the Treatment of Malignant Glioma |
$12,753,854 |
University of California, Davis |
Mehrdad Abedi |
Alpha Stem Cell Clinics Network Expansion |
Alpha Stem Cell Clinic for Northern and Central California |
$8,076,421 |
UCSF Benioff Children’s Hospital Oakland |
Mark Walters |
Alpha Stem Cell Clinics Network Expansion |
University of California, San Francisco (UCSF) CIRM Alpha Stem Cell Clinic |
$2,292,611 |
University of California, San Francisco |
Mark Walters |
Alpha Stem Cell Clinics Network Expansion |
University of California, San Francisco (UCSF) CIRM Alpha Stem Cell Clinic |
$5,707,388 |
Angiocrine Bioscience, Inc. |
Edward Kavalerchik |
Clinical Trial Stage Projects |
AB-110-001 Phase 1b Trial and Related Activities to Support Clinical Development of AB-110 |
$5,000,000 |
University of California, San Diego |
Thomas Kipps |
Clinical Trial Stage Projects |
A Phase 1b/2a Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in B-Cell Cancers |
$18,292,674 |
International Alliance for Biological Standardization |
Anthony Lubiniecki |
Conference - Manage a Symposium on Pluripotent Stem Cell Manufacturing |
Basis of Standardization for Cell Therapies |
$100,000 |
University of California, San Diego |
Ezra Cohen |
Therapeutic Translational Research Projects |
Development of ROR1 CAR-T cells to target cancer stem cells in advanced malignancies |
$5,795,584 |
BrainStorm Cell Therapeutics |
Ralph Kern |
Clinical Trial Stage Projects |
A Phase 3, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy & Safety of Repeated Administrations of NurOwn® in Patients with ALS |
$15,912,390 |
JDRF International |
Esther Latres |
Conference II |
JDRF Encapsulation Consortium Fall 2017 Meeting |
$42,425 |
X-Therma Inc. |
Xiaoxi Wei |
Quest - Discovery Stage Research Projects |
Non-Toxic, Highly-Effective Bioinspired Cryoprotectants for On-Demand Stem Cell Therapies |
$887,883 |
University of California, Los Angeles |
Gay Crooks |
Quest - Discovery Stage Research Projects |
Platform Technology for Pluripotent Stem Cell-Derived T cell Immunotherapy |
$965,636 |
Rumi Scientific CA |
Ali Brivanlou |
Quest - Discovery Stage Research Projects |
Discovery of therapeutics for Huntington’s Disease |
$1,399,800 |
University of California, Los Angeles |
Vaithilingaraja Arumugaswami |
Quest - Discovery Stage Research Projects |
Immunization strategies to prevent Zika viral congenital eye and brain disease |
$2,128,867 |
University of California, Irvine |
Brian Cummings |
Quest - Discovery Stage Research Projects |
Identification and characterization of the optimal human neural stem cell line (hNSC) for the treatment of traumatic brain injury (TBI) 2.0. |
$1,671,213 |
City of Hope, Beckman Research Institute |
Markus Müschen |
Quest - Discovery Stage Research Projects |
Lgr5-mediated self-renewal in B cell selection and leukemia-initiation |
$2,186,520 |
Stanford University |
Gary Steinberg |
Late Stage Preclinical Projects |
Intraparenchymal NR1 Stem Cell Therapy for Chronic Subcortical Ischemic Stroke |
$5,300,000 |
Scaled Biolabs Inc. |
Justin Cooper-White |
Quest - Discovery Stage Research Projects |
A tool for rapid development of clinical-grade protocols for dopaminergic neuronal differentiation of Parkinson’s Disease patient-derived iPSCs |
$657,528 |
Cellerant Therapeutics, Inc. |
Swapna Panuganti |
Late Stage Preclinical Projects |
Development of CLT030-ADC, a Leukemic Stem Cell Targeting Antibody-Drug-Conjugate, for Treatment of Acute Myeloid Leukemia |
$6,863,755 |
University of California, San Diego |
Yuan Chen |
Quest - Discovery Stage Research Projects |
A Novel Approach to Eradicate Cancer Stem Cells |
$279,977 |
University of California, San Francisco |
Holger Willenbring |
Quest - Discovery Stage Research Projects |
Preclinical development of AAV vector-mediated in vivo hepatic reprogramming of myofibroblasts as a therapy for liver fibrosis |
$1,638,389 |
SanBio, Inc. |
Bijan Nejadnik |
Clinical Trial Stage Projects |
A Double-Blind, Controlled Ph 2b Study of the Safety and Efficacy of Modified Stem Cells in Patients with Chronic Motor Deficit from Ischemic Stroke |
$18,970,000 |
University of California, Berkeley |
Kevin Healy |
Quest - Discovery Stage Research Projects |
Human Cardiac Chip for Assessment of Proarrhythmic Risk |
$899,581 |
University of California, San Francisco |
Tippi MacKenzie |
Clinical Trial Stage Projects |
In Utero Hematopoietic Stem Cell Transplantation For The Treatment Of Fetuses With Alpha Thalassemia Major |
$10,906,978 |
City of Hope, Beckman Research Institute |
Yuan Chen |
Quest - Discovery Stage Research Projects |
A Novel Approach to Eradicate Cancer Stem Cells |
$1,539,935 |
Stanford University |
Mark Mercola |
Quest - Discovery Stage Research Projects |
Multipotent Cardiovascular Progenitor Regeneration of the Myocardium after MI |
$1,809,234 |
University of California, Davis |
Deborah Lieu |
Quest - Discovery Stage Research Projects |
Microenvironment for hiPSC-derived pacemaking cardiomyocytes |
$2,042,438 |
University of California, Los Angeles |
Caroline Kuo |
Quest - Discovery Stage Research Projects |
Targeted Gene Editing in the Treatment of X-Linked Hyper-IgM Syndrome |
$1,512,333 |
University of Southern California |
Biju Thomas |
Inception - Discovery Stage Research Projects |
A Novel Tissue Engineering Technique to Repair Degenerated Retina |
$215,133 |
University of California, San Francisco |
Sonja Schrepfer |
Inception - Discovery Stage Research Projects |
Hypo-immunogenic cardiac patches for myocardial regeneration |
$235,818 |
Sanford Burnham Prebys Medical Discovery Institute |
Alessandra Sacco |
Inception - Discovery Stage Research Projects |
Generation of expandable, self-renewing muscle stem cells for Duchenne Muscular Dystrophy |
$252,000 |
Stanford University |
Helen Blau |
Inception - Discovery Stage Research Projects |
Prodrug innovation to target muscle stem cells and enhance muscle regeneration |
$235,834 |